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SERUM OESTRADIOL-17/7, testosterone,
luteinizing hormone (LH) and follicle-
stimulating hormone (FSH) concentra-
tions were measured by radioimmuno-
assay in the serum of 10 human males
with malignant breast disease. The mean
concentrations of oestradiol-17f7, LH and
FSH were not significantly different from
those of normal control males of com-
parable age. After correcting for the effect
of age on testosterone concentration, the
difference between the adjusted means for
males with breast cancer and controls was
not statistically significant.
In normal males, oestrone and oest-
radiol-17,B are partly produced by trans-
formation of androgen precursors, andro-
stenedione and testosterone, and partly
secreted directly by the testis. The
possibility of a relationship between
oestrogen metabolism and breast cancer
in the male has frequently been suggested.
Previous observations on oestrogen out-
put in males with breast cancer have been
contradictory. De Giuli & De Giuli (1973)
and Dao et al. (1973) reported higher total
urinary oestrogen concentrations in men
with breast cancer than in normal con-
trols. Scheike et al. (1973) found no change
in the urinary excretion pattern of males
with breast cancer. Radioimmunoassay of
plasma oestrogens and androgens, per-
formed by Calabresi et al. (1976) on 17
human males with breast cancer, showed
significantly higher amounts of endo-
genous oestrogens than in controls of
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comparable age, while finding no differ-
ence in plasma levels of androstenedione
or testosterone.
The present study was undertaken to
measure by radioimmunoassay oestradiol-
17/ in the serum of male breast-cancer
patients to determine whether there was
an excess of this oestrogen over normal
controls of comparable age; also, to deter-
mine whether such an excess was elicited
from the testis by an abnormal stimulation
by LH and FSH, or whether the excess of
oestrogen was transformed from a high
level of its precursor, testosterone.
During this study, 3 ofthe patients had
biopsy specimens taken from skin meta-
stases, and the tissue was then assayed for
receptor sites for oestradiol-173 and pro-
gesterone. Leclereq et al. (1976) reported
6 out of 7 primary tumours in men with
positive oestrogen-receptor activity, and
one out of 3 patients with metastatic
disease had receptor sites in tissue biopsy
material.
The investigations were performed on
10 men aged between 30 and 75 years
with histologically proven carcinoma.
Blood samples were taken before the start
ofprimary treatment.
Control studies were carried out on 31
men with a mean age of 61-9 years (range
37-89) who were free from any evidence of
disease or history of chronic illness, and
none of whom were taking any drugs, in-
cluding hormones.
Blood was collected in plain tubes,SERUM HORMONES IN MALE BREAST CANCER
between 09.00 and 10.00, allowed to clot
at room temperature and the serum
obtained by centrifugation. Serum was
stored at -20TC until analysed. Breast
tissue from biopsy was collected and
stored in liquid N2 until assayed for
oestrogen and progesterone receptor
activity.
Serum oestradiol-17/ was measured by
radioimmunoassay by the method pre-
viously described for postmenopausal
women (England et al. 1974), testosterone
by the method of Wheeler (1977).
Serum LH and FSH were determined by
double antibody radioimmunoassay using
I.R.P. 69/104 supplied by the World
Health Organisation to cover a range of
2-50 iu/l for both hormones. For each
hormone, the sera from both patients and
controls were measured on the same assay
to eliminate interassay variation.
Oestradiol-17/ and progesterone re-
ceptor assays were carried out by the DCC
method of Barnes et al. (1977).
TABLE I.-Serum hormones in male breast
cancer
Subject
RS
JM
GV
JB
FF
wC
FB
AW
CFW
HH
Mean
+s.d.
Range
Age
30
46
47
50
61
64
66
69
72
75
58
14 3
30-75
Oestra-
diol-17#
(pM)
154
29
66
84
51
84
204
80
70
125
94.7
52 2
29-204
Testo-
sterone
(nM)
244
33 6
29 4
31 6
10-4
144
18 3
27 2
200
17 6
22 7
7.7
104-336
LH
(iu/l)
3
7
2
2
10
5
13
6
5
7
6 0
3.5
2-13
FSH
(iu/l)
6
3
3
5
18
2
4
2
2
25
7 0
7.9
2-25
Table I shows the serum hormone con-
centrations observed in the 10 male
patients with breast carcinoma, Table II
the concentrations found in 31 healthy
males. The mean values of the breast-
cancer males showed no statistically sig-
nificant difference from the controls for
oestradiol-17/3 (z= 1.53, P=0.13), LH
(z=0-41, P=0.68) or FSH (z= 1.12, P=
0 26). Distribution of oestradiol-173 re-
TABLE II.-Serum hormones in healthy
males
Oestra- Testo-
diol-17f sterone LH FSH
Age (pM) (nM) (iu/i) (iu/1)
37 81 172 3 2
39 55 17*2 3 3
45 40 26 6 6 2
45 62 16 0 4 <2
50 66 288 3 2
50 15 189 7 9
50 37 19 2 10 11
52 70 26 6 5 3
55 81 80 6 2
55 85 205 5 5
55 88 23 7 4 <2
56 99 230 9 10
57 70 26 6 6 <2
58 55 21-1 8 18
60 48 6 8 3 3
62 40 27 5 5 9
63 95 10-0 2 3
64 48 10-0 3 3
66 85 17 3 6 <2
66 26 6 7 6 <2
67 40 99 4 <2
69 51 99 5 <2
71 29 14 1 5 <2
71 63 23-0 3 6
73 217 27 2 15 7
74 59 20 8 4 <2
76 107 8.3 3 <2
77 22 55 5 5
78 15 70 5 9
88 88 11 5 7 9
89 132 12 5 7 6
Mean 619 667 168 54 44
+s.d. 13 1 39 6 7*4 2 6 4-1
Range 37-89 15-217 5 5-28 8 2-15 < 2-18
sults about the mean was approximately
"normal". Distributions of both FSH and
LH concentrations were skewed, and the
non-parametric Mann-Whitney U test
was applied.
There was a significant correlation be-
tween age and testosterone concentration
in the group of normal males (r= - 0-42,
P 0.02) as shown in the Figure. The
testosterone concentrations in the breast-
cancer group, however, showed no sig-
nificant correlation with age. Since the
mean ages differ between the 2 groups,
the difference between the groups in mean
testosterone concentrations was tested
after correcting for the effect of age. The
difference between adjusted means was
not statistically significant: t= 1 96, df=
39, P - 0-06.
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FIG.-Serum testosterone as a function of
age in normal males.
No specific receptor sites for oestradiol-
17f or progesterone were found in the
tumour tissue from the 3 patients from
whom biopsy samples of skin metastases
had been taken.
The results ofthis study cannot confirm
the work previously reported by Calabresi
et al. (1976). We do not find significantly
higher concentrations of oestradiol-17f in
the serum of men with breast cancer than
in normal controls. On the contrary, the
data support the findings of Scheike et al.
(1973) who found no abnormality in the
metabolism of oestradiol-178 in men with
breast cancer nor any significant change in
urinary oestrogen.
Serum gonadotrophins show an upward
trend with age (Baker et al., 1976). LH is
primarily involved with Leydig-cell pro-
duction of testosterone, FSH seems to be
connected with seminiferous-tubule func-
tion, partly by direct stimulation of the
cells of Sertoli, and may be responsible for
controlling oestradiol-173 synthesis (Dor-
rington & Armstrong, 1975). Elevated LH
and FSH levels are associated with a
decline in testicular function. Oestradiol-
17P concentrations in blood tend to in-
crease with increasing age in normal men
after about the fifth decade, but the in-
crease is relatively small, whereas testo-
sterone levels decline steadily from the age
of 40, and men over 50 had significantly
lower levels of testosterone than younger
men (Baker et al., 1976). In our own group
of normal males (see Figure) there was a
significant negative correlation between
age and testosterone concentration,
though the correlation was not significant
for the small sample of breast-cancer
patients.
Individual variation in the age at which
oestradiol-17/3 starts to increase could bias
results in either direction, in either test or
control groups, especially when the num-
bers involved are small. It would seem
that in order to examine differences in
steroid hormone concentrations the
patients and controls should be divided
into groups, not only dependent on age,
but also upon the degree of progress
towards the "male menopause". This
would mean splitting an already small
group into even smaller ones, and results
would be meaningless.
In this study we find no difference
between the groups for any of the hor-
mones measured.
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